Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis

Background Generalized AChR-MG is an archetype of B cell-mediated autoimmune disorders, and use of biologic agent rituximab (RTX) for B cell depletion is generally limited to immunosuppressive therapy-refractory cases. However, benefit of RTX monotherapy and individualized regimen with optimal dosag...

Ausführliche Beschreibung